Just like the first participant, who we reported developed severe spinal inflammation, this second one also manifested the exact same disease, which AstraZeneca claims is “rare” and unrelated to its clinical trials.
After facing a barrage of criticism for its failure to disclose the details of its ongoing human trials, AstraZeneca reluctantly released data suggesting that transverse myelitis is a potential negative outcome of getting vaccinated for the Wuhan coronavirus (COVID-19).
The company’s trials, which are being conducted in conjunction with the University of Oxford, were quickly resumed after the first victim was deemed to have had an undiagnosed case of multiple sclerosis. Now, AstraZeneca will have to come up with another excuse for this second victim.
According to the company, which has already administered its experimental Wuhan coronavirus (COVID-19) vaccine to some 18,000 human guinea pigs worldwide, this latest case of transverse myelitis is “unlikely to be associated with the vaccine, or there was insufficient evidence to say for certain that the illnesses were or were not related to the vaccine.”
Since vaccine corporations have already been granted full legal immunity under President Trump’s “Operation Warp Speed” program, AstraZeneca need not worry as this is just another temporary roadblock to the eventual commercial approval of this monkey adenovirus-based jab....<<<Read The Full Article Here>>>...
